"Dasatinib_Anhydrous"^^ . _:b666012 . . _:b666014 . . "Dasatinib Anhydrous"^^ . "C22H26ClN7O2S"^^ . _:b666013 . _:b666015 . "C74556"^^ . _:b666013 . . _:b666012 . _:b666015 . _:b666015 . _:b666013 . _:b666014 . "DASATINIB ANHYDROUSPTFDAX78UG0A0RN" . _:b666016 . . _:b666012 . "X78UG0A0RN"^^ . . . _:b666012 . _:b666013 . "FDA"^^ . _:b666014 . "Dasatinib Anhydrous"^^ . _:b666015 . _:b666016 . _:b666016 . "Pharmacologic Substance"^^ . . "CHEBI:49375"^^ . "An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.NCI" . _:b666014 . "302962-49-8"^^ . _:b666016 . "C2699562"^^ . "Dasatinib AnhydrousPTNCI" . .